TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease

AIMS: To evaluate the potential superiority of donanemab vs. aducanumab on the percentage of participants with amyloid plaque clearance (≤24.1 Centiloids [CL]) at 6 months in patients with early symptomatic Alzheimer's disease (AD) in phase 3 TRAILBLAZER-ALZ-4 study. The amyloid cascade in AD i...

Descripción completa

Detalles Bibliográficos
Autores principales: Salloway, Stephen, Lee, Elly, Papka, Michelle, Pain, Andrew, Oru, Ena, Ferguson, Margaret B., Wang, Hong, Case, Michael, Lu, Ming, Collins, Emily C, Brooks, Dawn A., Sims, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345621/
http://dx.doi.org/10.1192/bjo.2023.227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345621/
http://dx.doi.org/10.1192/bjo.2023.227

Ejemplares similares